Biogen
Trade Biogen 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
As of today, Biogen(BIIB) shares are valued at $179.28. The company's market cap stands at 26.03B, with a P/E ratio of 20.18.
As of 2026-04-20, Biogen(BIIB) stock has fluctuated between $179.28 and $179.28. The current price stands at $179.28, placing the stock 0.0% above today's low and 0.0% off the high.
The Biogen(BIIB)'s current trading volume is 2.46K, compared to an average daily volume of 1.41M.
In the last year, Biogen(BIIB) shares hit a 52-week high of $202.41 and a 52-week low of $115.25.
In the last year, Biogen(BIIB) shares hit a 52-week high of $202.41 and a 52-week low of $115.25.
BIIB News
Biogen (BIIB) and TJ Biopharma announced that the companies have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bio’s exclusive...
Wells Fargo analyst Mohit Bansal upgraded Biogen (BIIB) to Overweight from Equal Weight with a $250 price target Published first on TheFly – the ultimate sourc...
Biogen (NasdaqGS:BIIB) agreed to acquire Apellis Pharmaceuticals in a deal valued at US$5.6b. The agreement follows multiple competing bids and months of negot...
Analyst ratings
51%
of 37 ratingsMore BIIB News
Analysts are intrested in these 5 stocks: ( (SPOT) ), ( (SNDK) ), ( (NTRA) ), ( (BIIB) ) and ( (TSLA) ). Here is a breakdown of their recent ratings and the rat...
As previously reported, Wells Fargo analyst Derek Archila downgraded Apellis (APLS) to Equal Weight from Overweight with a price target of $41, up from $26. The...
Key Points Biogen's quarterly updates haven't been impressive of late. It has made regulatory progress, but that won't be enough to boost top-line growth this...
On 7 April 2026, Alloy Therapeutics announced a collaboration and license agreement granting Biogen access to its proprietary AntiClastic antisense oligonucleot...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.